• Login
    View Item 
    •   QMU Repositories
    • eResearch
    • School of Health Sciences
    • Dietetics, Nutrition and Biological Sciences
    • View Item
    •   QMU Repositories
    • eResearch
    • School of Health Sciences
    • Dietetics, Nutrition and Biological Sciences
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.

    Access
    none
    Date
    2005-08
    Author
    Gault, Victor A.
    Irwin, Nigel
    Green, Brian D.
    McCluskey, Jane T.
    Greer, Brett
    Bailey, Clifford J.
    Harriott, Patrick
    O'harte, Finbarr P. M.
    Flatt, Peter R.
    Metadata
    Show full item record
    Citation
    Gault, V., Irwin, N., Green, B., McCluskey, J., Greer, B., Bailey, C., Harriott, P., O''harte, F. & Flatt, P. (2005) Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes., Diabetes, vol. 54, , pp. 2436-46,
    Abstract
    Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide [GIP]) is an important incretin hormone secreted by endocrine K-cells in response to nutrient ingestion. In this study, we investigated the effects of chemical ablation of GIP receptor (GIP-R) action on aspects of obesity-related diabetes using a stable and specific GIP-R antagonist, (Pro3)GIP. Young adult ob/ob mice received once-daily intraperitoneal injections of saline vehicle or (Pro3)GIP over an 11-day period. Nonfasting plasma glucose levels and the overall glycemic excursion (area under the curve) to a glucose load were significantly reduced (1.6-fold; P < 0.05) in (Pro3)GIP-treated mice compared with controls. GIP-R ablation also significantly lowered overall plasma glucose (1.4-fold; P < 0.05) and insulin (1.5-fold; P < 0.05) responses to feeding. These changes were associated with significantly enhanced (1.6-fold; P < 0.05) insulin sensitivity in the (Pro3)GIP-treated group. Daily injection of (Pro3)GIP reduced pancreatic insulin content (1.3-fold; P < 0.05) and partially corrected the obesity-related islet hypertrophy and beta-cell hyperplasia of ob/ob mice. These comprehensive beneficial effects of (Pro3)GIP were reversed 9 days after cessation of treatment and were independent of food intake and body weight, which were unchanged. These studies highlight a role for GIP in obesity-related glucose intolerance and emphasize the potential of specific GIP-R antagonists as a new class of drugs for the alleviation of insulin resistance and treatment of type 2 diabetes.
    Type
    article
    Official URL
    https://doi.org/10.2337/diabetes.54.8.2436
    URI
    https://eresearch.qmu.ac.uk/handle/20.500.12289/4497
    Collections
    • Dietetics, Nutrition and Biological Sciences

    Queen Margaret University: Research Repositories
    Contact Us | Send Feedback
     

     

    Browse

    All QMU RepositoriesCommunities & CollectionsBy YearBy PersonBy TitleBy QMU AuthorBy Research CentreThis CollectionBy YearBy PersonBy TitleBy QMU AuthorBy Research Centre

    My Account

    LoginRegister

    Queen Margaret University: Research Repositories
    Contact Us | Send Feedback